AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient Community Rheumatology Practice, Is More Cost-Effective Than CAR-T Treatments for Rheumatologic Diseases | Synapse
March 3, 2026
AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient Community Rheumatology Practice, Is More Cost-Effective Than CAR-T Treatments for Rheumatologic Diseases
Key Points
AB-101 NK cell therapy demonstrates higher cost-effectiveness compared to CAR-T treatments, especially in outpatient settings.
Cost savings were significant, reducing financial burdens for patients needing rheumatologic disease therapy.
The analysis focuses on outpatient community rheumatology practices, indicating a shift in treatment approaches.
Findings suggest potential for broader use of NK cell therapy, enhancing patient access to care in rheumatologic disorders.